An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension

N/ACompletedNCT01201980

AstraZeneca300 enrolled

Overview

This study is aimed to evaluate response rate of the antihypertensive treatment with a calcium antagonist in real life practice, to evaluate patients' quality of life and to collect the following Serbia-specific epidemiology data on hypertension: demographic data, patents characteristics, and patients' management/treatment.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Hypertension

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist

Locations (8)

Research Site

Belgrade, Serbia

Research Site

Čačak, Serbia

Research Site

Kamenitz, Serbia

Research Site

Kragujevac, Serbia

Outcomes

Primary Outcomes

To evaluate proportion of patients on antihypertensive pharmacological treatment reaching SBP goals according to the ESC 2007 guidelines (<140 mmHg*).

Time frame: 24 weeks

Secondary Outcomes

To evaluate proportion of patients on antihypertensive pharmacological treatment reaching DBP goals according to the ESC 2007 guidelines (<90 mmHg*).

Time frame: 24 weeks

To collect local epidemiological date on patients with hypertension (demographic data; hypertension management data: treatment, treatment changes and tolerability data).

Time frame: 24 weeks

To evaluate patients quality of life after 12 and 24 weeks by using patients quality of life questionnaire

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.